PHV-wordings
Here you will find safety-relevant information that must be implemented in the corresponding product information due to a PHV (pharmacovigilance) issues.
Due to the relaunch of the EMA website in December 2023, you will find the current links to the entries prior to December 01, 2023 at https://www.ema.europa.eu
Tapentadol
				
	
	
		
			PSUR-outcome
		
	
	|
09/09/2022
			
			
				
		
	
			Further information and amendments to the product information in all EU languages are available on the EMA website.
		
		
	
		
	
	
			
		NSAID-containing medicinal products (for systemic use)
				
	
	
		
			Additional template
		
	
	|
09/09/2022
			
			
				
		
	
			Further information is available in the CMDh press release (Report from the meeting held on 13-14 September 2022 and Report from the meeting held on 19-20 July 2022) on the HMA-Website.
		
		
	
		
	
	
			
		NSAIDs Ibuprofen (for systemic use)
				
	
	
		
			Additional template
		
	
	|
26/08/2022
			
			
				
		
	Further information is available in the CMDh press release (Report from the meeting held on 19-20 July 2022) on the HMA-Website.
		
	
		
	
	
			
		Dexketoprofen
				
	
	
		
			PSUR-outcome
		
	
	|
16/08/2022
			
			
				
		
	Further information and amendments to the product information in all EU languages are available on the EMA website.
		
	
		
	
	
			
		Soybean phospholipids (oral use)
				
	
	
		
			PSUR-outcome
		
	
	|
16/08/2022
			
			
				
		
	Further information and amendments to the product information in all EU languages are available on the EMA website.
		
	
		
	
	
			
		Diclofenac systemisch
				
	
	
		
			PSUR-outcome
		
	
	|
11/08/2022
			
			
				
		
	Further information and amendments to the product information in all EU languages are available on the EMA website.
		
	
		
	
	
			
		Teicoplanin
				
	
	
		
			PSUR-outcome
		
	
	|
08/08/2022
			
			
				
		
	Further information and amendments to the product information in all EU languages are available on the EMA website.
		
	
		
	
	
			
		Methylphenidate
				
	
	
		
			PSUR-outcome
		
	
	|
08/08/2022
			
			
				
		
	Further information and amendments to the product information in all EU languages are available on the EMA website.
		
	
		
	
	
			
		Rabeprazole
				
	
	
		
			PSUR-outcome
		
	
	|
08/08/2022
			
			
				
		
	Further information and amendments to the product information in all EU languages are available on the EMA website.
		
	
		
	
	
			
		Alfentanil
				
	
	
		
			PSUR-outcome
		
	
	|
05/07/2022
			
			
				
		
	
			Further information and amendments to the product information in all EU languages are available on the EMA website.